#	Pagina
attuale pagina	/open-h2020/projects/199744/index.html
-1	/open-fp7/projects/109240/index.html
-2	/open-h2020/projects/221896/index.html
-3	/open-h2020/per-topic/hypervariabity/list/index.html
-4	/open-h2020/projects/202581/index.html
-5	/open-h2020/projects/196822/index.html
-6	/open-h2020/projects/202592/index.html
-7	/open-h2020/projects/221374/index.html
-8	/open-fp7/projects/98215/index.html
-9	/open-h2020/projects/218988/index.html
-10	/open-fp7/projects/188198/index.html

Opendata, web and dolomites

CARAT SIGNED

Chimeric Antigen Receptors (CARs) for Advanced Therapies

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

CARAT project word cloud

Explore the words cloud of the CARAT project. It provides you a very rough idea of what is the project "CARAT" about.

broadly gene solid technological compliance innovative ill serving assemble translation overcome safer compliant empower clinics envisaged obstacles commercialisation genetically genetic act potency delivering killing safety efficient prodigy vision clinimacs thereby gmp hematologic off consequently artificial extremely patients generation regulatory handle manufacture carat therapies scientific respect summary elevate cellular obtain antibodies molecules disseminate cancer engineering therapy stories recognition somatic global tumours cells car antigen surface raised public platform automated simplified breakthrough modified chimeric atmp technologies cell explicitly hurdles enormous leader standard applicable expensive cure cars malignancies care redirect receptors expectations tools proof severely incurable

Project "CARAT" data sheet

The following table provides information about the project.

Coordinator	MILTENYI BIOTEC GMBH Organization address address: FRIEDRICH EBERT STRASSE 68 city: BERGISH GLADBACH postcode: 51429 website: www.miltenyibiotec.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Germany [DE]
Project website	http://carat-horizon2020.eu/
Total cost	5˙989˙158 €
EC max contribution	5˙989˙158 € (100%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-PHC-2015-two-stage
Funding Scheme	RIA
Starting year	2016
Duration (year-month-day)	from 2016-01-01 to 2019-12-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	MILTENYI BIOTEC GMBH MILTENYI BIOTEC GMBH Organization address address: FRIEDRICH EBERT STRASSE 68 city: BERGISH GLADBACH postcode: 51429 website: www.miltenyibiotec.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (BERGISH GLADBACH)	coordinator	1˙349˙760.00
2	OSPEDALE SAN RAFFAELE SRL OSPEDALE SAN RAFFAELE SRL Organization address address: VIA OLGETTINA 60 city: MILANO postcode: 20132 website: www.hsr.it contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (MILANO)	participant	913˙300.00
3	UNIVERSITAETSKLINIKUM FREIBURG UNIVERSITAETSKLINIKUM FREIBURG Organization address address: HUGSTETTER STRASSE 49 city: FREIBURG postcode: 79106 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (FREIBURG)	participant	718˙580.00
4	BUNDESINSTITUT FUR IMPFSTOFFE UND BIOMEDIZINISCHE ARZNEIMITTEL BUNDESINSTITUT FUR IMPFSTOFFE UND BIOMEDIZINISCHE ARZNEIMITTEL Organization address address: PAUL-EHRLICH-STRASSE 51-59 city: LANGEN postcode: 63225 website: www.pei.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (LANGEN)	participant	714˙825.00
5	UNIVERSITY COLLEGE LONDON UNIVERSITY COLLEGE LONDON Organization address address: GOWER STREET city: LONDON postcode: WC1E 6BT website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (LONDON)	participant	660˙398.00
6	INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE Organization address address: RUE DE TOLBIAC 101 city: PARIS postcode: 75654 website: www.inserm.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (PARIS)	participant	646˙770.00
7	EURICE EUROPEAN RESEARCH AND PROJECT OFFICE GMBH EURICE EUROPEAN RESEARCH AND PROJECT OFFICE GMBH Organization address address: HEINRICH-HERTZ-ALLEE 1 city: ST INGBERT postcode: 66386 website: www.eurice.eu contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (ST INGBERT)	participant	562˙775.00
8	TRAKCEL LIMITED TRAKCEL LIMITED Organization address address: 10/11 RALEIGH WALK BRIGANTINE PLACE city: CARDIFF postcode: CF10 4LN website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (CARDIFF)	participant	422˙750.00

Map

Project objective

Chimeric antigen receptors (CARs) are artificial surface receptors that can be introduced into somatic cells by genetic engineering and that act as recognition molecules like antibodies or T-cell receptors. In this respect, CARs are increasingly used for cellular therapy to redirect T-cells specifically towards killing of cancer cells. Recent success stories of cancer therapy with CAR modified T-cells have raised enormous scientific and public expectations to cure severely ill patients. However, there are still many obstacles to overcome for translation into clinics because the technology for GMP-compliant manufacture of genetically modified cellular products is extremely complex and expensive. Moreover, CAR therapy needs to be improved with respect to off-target activity, safety and potency. Consequently, the envisaged project is overall aiming at a particular technological breakthrough in cellular cancer therapy by delivering a comprehensive CARAT platform explicitly tailored for automated, easy-to-handle and cost-efficient manufacture of CAR-modified ATMP. Specifically, we aim:

(a) to implement unique next-generation cell processing tools like the CliniMACS Prodigy (b) to develop advanced enabling technologies to obtain more effective and safer cellular products by improved gene delivery and innovative CARs design (c) to assemble tools and technologies towards an integrated CARAT process for automated GMP-compliant manufacture of gene-modified T-cells (d) to demonstrate proof-of-concept and regulatory compliance (e) to disseminate broadly applicable, simplified CAR T-cell technologies

In summary, our vision is to overcome current hurdles for translation of cellular therapies and to elevate them to the next level of standard-of-care thus serving patients with so far incurable solid tumours and hematologic malignancies. Thereby, we will empower Europe to become a global leader in the development and commercialisation of CAR T-cell tools and technologies.

Deliverables

List of deliverables.
Project website	Websites, patent fillings, videos etc.	2019-10-14 12:21:24

Take a look to the deliverables list in detail: detailed list of CARAT deliverables.

Publications

List of publications.
year	authors and title	journal	last update
2017	Dominik Lock, Nadine Mockel-Tenbrinck, Katharina Drechsel, Carola Barth, Daniela Mauer, Thomas Schaser, Carolin Kolbe, Wael Al Rawashdeh, Janina Brauner, Olaf Hardt, Natali Pflug, Udo Holtick, Peter Borchmann, Mario Assenmacher, Andrew Kaiser Automated Manufacturing of Potent CD20-Directed Chimeric Antigen Receptor T Cells for Clinical Use published pages: 914-925, ISSN: 1043-0342, DOI: 10.1089/hum.2017.111	Human Gene Therapy 28/10	2019-10-14
2017	S. A. Haas, V. Dettmer, T. Cathomen Therapeutic genome editing with engineered nucleases published pages: 45-52, ISSN: 0720-9355, DOI: 10.5482/HAMO-16-09-0035	HÃ¤mostaseologie 37/1	2019-10-14
2017	Jessica Hartmann, Martina SchÃ¼ÃŸlerâ€Lenz, Attilio Bondanza, Christian J Buchholz Clinical development of CAR T cellsâ€”challenges and opportunities in translating innovative treatment concepts published pages: e201607485, ISSN: 1757-4676, DOI: 10.15252/emmm.201607485	EMBO Molecular Medicine	2019-10-14
2017	Elisa Peranzoni, Houcine Bougherara, Sarah Barrin, Audrey Mansuet-Lupo, Marco Alifano, Diane Damotte, Emmanuel Donnadieu Ex Vivo Imaging of Resident CD8 T Lymphocytes in Human Lung Tumor Slices Using Confocal Microscopy published pages: , ISSN: 1940-087X, DOI: 10.3791/55709	Journal of Visualized Experiments 130	2019-10-14

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CARAT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CARAT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

CLOSER (2019)

Childhood Leukemia: Overcoming distance between South America and Europe Regions

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

ESCALON (2019)

European-Latin American network for the assessment of biomarkers to predict and diagnose hepatobiliary malignancies and characterization of risk factors for cancer development